QUOTE AND NEWS
newratings.com  5 hrs ago  Comment 
BASEL (dpa-AFX) - Novartis (NVS) announced the establishment of FortiHFy, the largest global clinical program in the heart failure disease area across the pharma industry to date, comprising over 40 active or planned clinical studies designed to...
newratings.com  9 hrs ago  Comment 
BASEL (dpa-AFX) - Novartis (NVS) said it will highlight the strength of its oncology research programs at the upcoming 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), being held June 3-7 in Chicago. Data will demonstrate...
newratings.com  May 18  Comment 
Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting Novartis International AG / Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting . Processed and...
newratings.com  May 18  Comment 
BRUSSELS (dpa-AFX) - The Swiss stock market ended Wednesday's session with a significant increase. The market got off to a weak start, before staging a recovery and slipped back into the red in the afternoon. The market bounced back into the...
The Hindu Business Line  May 18  Comment 
Pharmed seeks RBI intervention In a new twist to the Wander Ltd (a Sandoz group company) takeover issue, Bangalore-based Pharmed Ltd has sought the intervention of RBI on what it alleges amounts t...
Reuters  May 18  Comment 
The door remains open for Swiss pharmaceutical company Novartis to reach a deal with Colombia to lower the cost of cancer drug imatinib and prevent the Andean country from allowing...
FiercePharma  May 18  Comment 
The mano-a-mano between Pfizer's Ibrance and Novartis' LEE011 nears with early PhIII wrap-up tracystaton Wed, 05/18/2016 - 10:57
The Economic Times  May 18  Comment 
The lab testing was stopped early because of its good results, plans to divide the pharmaceutical division in two unit,one focusing only on cancer drugs.




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki